MedTrace Logo

Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis

NCT03542838 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2021-04-01

No results posted yet for this study

Summary

This study evaluates the safety of resiniferatoxin in patients with moderate to severe knee pain due to osteoarthritis.

Conditions

  • Osteoarthritis, Knee
  • Pain, Knee

Interventions

DRUG

Resiniferatoxin

Resiniferatoxin is a compound purified from natural sources.

DRUG

Saline

Saline is a normal physiological solution

Sponsors & Collaborators

  • Sorrento Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Monica Luchi, MD · Sorrento Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-12
Primary Completion
2020-04-13
Completion
2021-02-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03542838 on ClinicalTrials.gov